In an effort to continue to fight cancer through advanced screenings, Exact Sciences and the Mayo Clinic have extended their collaboration for five more years, the companies announced recently.

According to a release, Exact Sciences will continue to have rights to certain intellectual property while working with Mayo Clinic gastroenterologist Dr. David Ahlquist.

“By expanding our relationship with Mayo Clinic, we have an opportunity to build on our shared successes and continue looking for new opportunities to take on some of the deadliest forms of cancer,” Exact Sciences President, CEO and Chairman Kevin Conroy said in a statement. “This collaboration and our ability to leverage both institutions’ distinctly different strengths is unique in American industry. We expect our collaboration to continue producing breakthroughs that can change patients’ lives.”

Cologuard is the first and only-FDA approved, noninvasive stool DNA screening test for colorectal cancer.